Abstracts tagged "SLE"

Abstract Number: 975 • 2019 ACR/ARP Annual Meeting
Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function
Abhimanyu Amarnani¹, Ramile Dilshat ², Nikita Malakhov ³, Brian Ghezelaiagh ⁴, Chongmin Huan ¹, Erna Magnusdottir ², Eirikur Steingrimsson ² and Christopher Roman ¹, ¹SUNY Downstate Medical Center, Brooklyn, ²University of Iceland Biomedical Center, Reykjavik, Iceland, ³SUNY Downstate Medical Center, New York Presbyterian-Weill Cornell Medical Center, Brooklyn, ⁴SUNY Downstate Medical Center, Stony Brook University, Brooklyn
Background/Purpose: Autoreactive B cells are central in the development of many autoimmune diseases, such as systemic lupus erythematosus (SLE), and are normally eliminated or inactivated…
Abstract Number: 1575 • 2019 ACR/ARP Annual Meeting
Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change
Sarit Sekhar Pattanaik¹, Ankita Singh ², Shilpa Venkataraman ³, Ramnath Misra ⁴, Vinita Agrawal ² and Amita Aggarwal ⁵, ¹Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Multiple urinary biomarkers have been described for lupus nephritis, however none has reached the clinic due to either complex methodology or low discriminatory power.…
Abstract Number: 1941 • 2019 ACR/ARP Annual Meeting
Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk
Jing Cui¹, Soumya Raychaudhuri ², Cameron Speyer ², Susan Malspeis ², Hongshu Guan ³, Xinyi Liu ², Jessica Williams ², Emma Davenport ⁴, Rachel Knevel ⁵, Elizabeth Karlson ² and Karen Costenbader ², ¹Brigham Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Sanger Institute, Cambridge, United Kingdom, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: We have previously reported that current smoking (or having recently quit within 4 years) was associated with elevated risk of SLE, in particular anti-dsDNA+…
Abstract Number: 2577 • 2019 ACR/ARP Annual Meeting
SLE Disease Activity May Be Associated with Choroidal Thickness
Iris Lee¹, Brigid Marshall ¹, Prabha Ranganathan ², Seth Eisen ³, Rithwick Rajagopal ¹, Alfred Kim ³ and Tingting Li ¹, ¹Washington University in St Louis, St Louis, ²Washington University in St Louis, St Louis, MO, ³Washington University School of Medicine, Saint Louis, MO
Background/Purpose: SLE is an autoimmune disease with widespread organ involvement. High disease activity has previously been associated with higher risk of organ damage and mortality.…
Abstract Number: 20 • 2018 ACR/ARHP Annual Meeting
Expression and Functions of the Transcription Factors Ikaros and Aiolos in Sjogren’s Syndrome and Systemic Lupus Erythematosus
Felice Rivellese^1,2, Daniele Mauro¹, Mattia Congia³, Elena Pontarini¹, Peter Schafer⁴, Michele Bombardieri^1,2, Costantino Pitzalis^1,5 and Myles J. Lewis^1,2, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kindgdom, London, United Kingdom, ²Barts Health NHS Trust & Barts and the London School of Medicine & Dentistry, London, United Kingdom, London, United Kingdom, ³Rheumatology and Rheumatology Unit, University Clinic and AOU of Cagliari, Cagliari, Italy, Cagliari, Italy, ⁴Celgene Corporation, Summit, NJ, ⁵Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: Polymorphisms of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are essential for the maturation, differentiation and survival of B cells, have been…
Abstract Number: 715 • 2018 ACR/ARHP Annual Meeting
Septic Shock Among Patients with Systemic Lupus Erythematosus: Short and Long-Term Outcome and Cost. Analysis of the French Nationwide Database
Arthur Mageau¹, Karim Sacre², Anne Perozziello¹, Stephane Ruckly¹, Claire Dupuis¹, Lila Bouadma¹, Thomas Papo¹ and Jean Francois Timsit¹, ¹Université Paris-Diderot, Paris, France, ²Bichat Hospital, Paris Diderot University, Paris, France
Background/Purpose: Infection is a leading cause of death and ICU admission in systemic lupus erythematosus (SLE) patients. Our aim was to investigate the outcome and…
Abstract Number: 1084 • 2018 ACR/ARHP Annual Meeting
Dysfunction of the DNASE1L3 Pathway and Antigen Accumulation in Lupus Nephritis
Johannes Hartl¹, Robert M. Clancy¹, Peter M. Izmirly², H. Michael Belmont¹, Nicole Kaiden³, Nicole Bornkamp³, Vanja Sisirak¹, Benjamin Sally¹, Jill P. Buyon¹ and Boris Reizis¹, ¹NYU School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Medicine, NYU School of Medicine, New York, NY
Background/Purpose: DNASE1L3 is a unique secreted DNase that is capable of degrading DNA complexed with proteins and/or encapsulated in membranes, such as chromatin within microparticles…
Abstract Number: 1942 • 2018 ACR/ARHP Annual Meeting
Anti-NMDA Receptor Antibodies in Systemic Lupus Erythematosus Associate with Decreased White Matter Integrity and Impaired Spatial Memory
Erik Anderson¹, An Vo², Elisabeth Ploran³, Betty Diamond², Bruce Volpe⁴, Cynthia Aranow², David Eidelberg² and Meggan Mackay², ¹Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ²The Feinstein Institute for Medical Research, Manhasset, NY, ³Hofstra University, Hempstead, NY, ⁴Biomedical Sciences, The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment is common in SLE and impacts quality of life; however, causality is limited by incomplete understanding of neurotoxic mechanisms. Diffusion tensor imaging…
Abstract Number: 2150 • 2018 ACR/ARHP Annual Meeting
Association of Poverty Income Ratio with Physical Functioning in a Cohort of Patients with Systemic Lupus Erythematosus
Courtney Hoge¹, C. Barrett Bowling², S. Sam Lim³, Cristina Drenkard⁴ and Laura Plantinga⁵, ¹Department of Epidemiology, Emory University, Atlanta, GA, ²Durham Veterans Affairs Medical Center, Durham, NC, ³Emory University School of Medicine, Atlanta, GA, ⁴Medicine/Rheumatology, Emory University, Atlanta, GA, ⁵Department of Medicine, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Lower socioeconomic status (SES) has been shown to be associated with poor physical functioning in systemic lupus erythematosus (SLE) patients; however, previous studies have…
Abstract Number: 2894 • 2018 ACR/ARHP Annual Meeting
Psychosis in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
John G. Hanly¹, Qiuju Li², Li Su³, Murray Urowitz⁴, Caroline Gordon⁵, Sang-Cheol Bae⁶, Juanita Romero-Díaz⁷, Jorge Sanchez-Guerrero⁴, Sasha Bernatsky⁸, Ann E. Clarke⁹, Daniel J. Wallace¹⁰, David A. Isenberg¹¹, Anisur Rahman¹², Joan T. Merrill¹³, Paul R. Fortin¹⁴, Dafna D Gladman¹⁵, Ian N. Bruce¹⁶, Michelle Petri¹⁷, Ellen M. Ginzler¹⁸, Mary Dooley¹⁹, Kristján Steinsson²⁰, Rosalind Ramsey-Goldman²¹, Asad A Zoma²², Susan Manzi²³, Ola Nived²⁴, Andreas Jönsen²⁴, Munther A Khamashta²⁵, Graciela S. Alarcón²⁶, Ronald F van Vollenhoven²⁷, Cynthia Aranow²⁸, Meggan Mackay²⁸, Guillermo Ruiz-Irastorza²⁹, Manuel Ramos-Casals³⁰, S. Sam Lim³¹, Murat Inanc³², Kenneth C. Kalunian³³, Søren Jacobsen³⁴, Christine A. Peschken³⁵, Diane L. Kamen³⁶, Anca Askanase³⁷, Chris Theriault³⁸ and Vernon Farewell³⁹, ¹Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²MRC Biostatistics Unit, Cambridge, United Kingdom, ³Nova Scotia Rehab Site, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴University of Toronto Lupus Research Program, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁸Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁰Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹¹University College London, London, United Kingdom, ¹²Rayne Institute, University College London, London, United Kingdom, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ¹⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ¹⁹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²⁰Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²¹FSM, Northwestern University, Chicago, IL, ²²Lanarkshire Center for Rheumatology, Hairmyres Hospital, East Kilbride, East Kilbride, Scotland, United Kingdom, ²³Autoimmunity Institute and Medicine Institute, Allegheny Health Network, Pittsburgh, PA, ²⁴Rheumatology, Lund University, Department of Clinical Sciences, Lund, Sweden, ²⁵Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ²⁶University of Alabama at Birmingham, Birmingham, AL, ²⁷Unit for clinical therapy research (ClinTRID), Karolinska Institute, Stockholm, Sweden, ²⁸The Feinstein Institute for Medical Research, Manhasset, NY, ²⁹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ³⁰Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ³¹Emory University School of Medicine, Atlanta, GA, ³²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³³Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³⁴Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁵RR 149G, University of Manitoba, Winnipeg, MB, Canada, ³⁶Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁷Rheumatology, Columbia University, College of Physician and Surgeons, New York, NY, ³⁸Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ³⁹Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Psychosis, one of the rarer neuropsychiatric (NP) events in lupus patients, features in both the ACR and Systemic Lupus International Collaborating Clinics (SLICC) classification…
Abstract Number: 27 • 2018 ACR/ARHP Annual Meeting
Top-Down Proteomics Coupled with Antibody Sequencing from Single B Cells Reveals a Monoclonal Anti-Sm Clone Present in the Serum of an SLE Patient over Three Years
Zhe Wang¹, Jennifer Muther², Judith A. James³, Si Wu¹ and Kenneth Smith², ¹Chemistry and Biochemistry, University of Oklahoma, Norman, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Proteomics is becoming an increasingly powerful tool to study autoantibodies. Current bottom-up approaches are yielding a plethora of knowledge about public clonotypes and clonal…
Abstract Number: 728 • 2018 ACR/ARHP Annual Meeting
A Higher Activity Index at Initial Renal Biopsy Is Associated with Rapid Progression to Renal Failure in Patients with Refractory Lupus Nephritis
Shuwei Wang¹, Stacy Tanner², Teja Kapoor³, Thania Perez⁴, Vivette D D'Agati⁵, Anca Askanase⁴, Robert Winchester³ and Laura Geraldino-Pardilla³, ¹Rheumatology, Columbia University, College of Physicians & Surgeons, New York City, NY, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, Winnipeg, DC, Canada, ³Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Columbia University, College of Physicians & Surgeons, New York, NY, ⁵Pathology & Cell Biology, Columbia University, College of Physicians & Surgeons, New York City, NY
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality affecting ~50% of systemic lupus erythematosus (SLE) patients. Up to 30% of patients…
Abstract Number: 1091 • 2018 ACR/ARHP Annual Meeting
Serine Arginine-Rich Splicing Factor 1 (SRSF1) Is Essential for T Lymphocyte Homeostasis and Decreased Levels of SRSF1 Correlate with Lymphopenia in SLE Patients
Takayuki Katsuyama¹, Kotaro Iida² and Vaishali R. Moulton¹, ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Division of Rheumatology, Department of Medicine, Boston, MA
Background/Purpose: Lymphopenia is one of the most common clinical features in patients with systemic lupus erythematosus (SLE), and associates with severe disease and comorbidities such…
Abstract Number: 1943 • 2018 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Associate with Poor Renal Outcomes, Damage Accrual, and Death: A Prospective Ghanaian SLE Cohort
Ashira Blazer¹, Ida Dzifa Dey², Margaret Reynolds³, Festus Ankrah³, Nancyanne Schmidt⁴, Robert M. Clancy⁵ and Jill P. Buyon⁶, ¹Internal Medicine Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Medicine, Rheumatology Unit, School of Medicine and Dentistry,University of Ghana, Accra, Ghana, ³Internal Medicine, The University of Ghana, Accra, Ghana, ⁴Internal Medicine, New York University School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Two Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, are enriched in ancestrally African populations due to a conferred superior resistance to Trypanosoma…
Abstract Number: 2170 • 2018 ACR/ARHP Annual Meeting
Relationship between Short- and Long-Term Periods of Self-Reported Physical Activity Patterns in Individuals with SLE
Gizem Irem Kinikli¹, Susanne Pettersson², Iva Gunnarsson³, Elisabet Svenungsson³ and Carina Boström⁴, ¹Physiotherapy and Rehabilitation, Hacettepe University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara/TURKEY, Ankara, Turkey, ²Neurobiology, care sciences and society, Karolinska Institutet, Department of Neurobiology, care sciences and society, Karolinska University Hospital, Stockholm/SWEDEN, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴Karolinska University Hospital, Karolinska Institutet, Department of Neurobiology, care sciences and society, Karolinska University Hospital, Stockholm/SWEDEN, Stockholm, Sweden
Background/Purpose: Physical inactivity is prevalent in Systemic Lupus Erythematosus (SLE). Assessment of physical activity (PA) is vital to manage cardiovascular risk factors in SLE. The…

« Previous Page
1
…
4
5
6
7
8
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].